Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) is a clinical-stage biopharmaceutical company focused on therapies built on its lipid nanocrystal (LNC) platform delivery technology. The Matinas news feed highlights developments around its lead antifungal candidate MAT2203, corporate strategy, and platform research, providing context for investors and observers tracking MTNB stock news.
Company news frequently covers clinical and medical updates for MAT2203, an oral formulation of amphotericin B being developed as a potential broad-spectrum treatment for invasive deadly fungal infections. Releases have described results from the Phase 2 EnACT study in HIV patients with cryptococcal meningitis, outcomes from the Compassionate/Expanded Use Access Program in patients with severe invasive fungal infections, and plans for the ORALTO Phase 3 registration trial in invasive aspergillosis. These items help readers understand how MAT2203 is performing in both controlled trials and real-world settings.
Matinas also issues corporate and strategic announcements, including updates on its strategic review, financing transactions such as preferred stock and warrant offerings, and responses to NYSE American listing notices. Board and governance news—such as the appointment of independent directors with expertise in biotechnology, healthcare, finance, and audit oversight, as well as director retirements and committee leadership changes—features prominently in the company’s communications.
In addition, the news stream includes scientific and platform data related to the LNC technology, such as in vitro and in vivo findings on LNC delivery of small oligonucleotides and chemotherapeutic agents, and conference presentations on intracellular delivery. Readers can use this page to follow how Matinas’ clinical programs, LNC platform research, and corporate actions evolve over time. For those monitoring MTNB, returning to this news page offers a centralized view of key press releases and event announcements.
Matinas BioPharma Holdings (NYSE: MTNB) reported progress in its clinical studies and financial results for Q3 2020. The EnACT study of MAT2203 for cryptococcal meningitis received a recommendation from the DSMB to proceed to the second cohort, with evaluations set for mid-2021. Enrollment in the ENHANCE-IT study of MAT9001 against Vascepa is complete, and topline data is expected in Q1 2021. The company ended the quarter with $62.8 million in cash and a net loss of $5.7 million. Management remains focused on advancing its drug candidates and anticipates sufficient funds for operations through H1 2023.
Matinas BioPharma Holdings (MTNB) will host a conference call and live webcast on November 6, 2020, at 8:30 a.m. ET, to discuss Q3 2020 operational and financial results. Interested participants can join via phone or through the Investors section of the Matinas website, where the event will also be archived for 90 days. The company, focused on next-generation therapeutics, is developing MAT9001 for hypertriglyceridemia and MAT2203 for invasive fungal infections. Topline data for MAT9001 is expected in Q1 2021, while MAT2203 is in a Phase 2 study.
Matinas BioPharma (MTNB) has received a unanimous recommendation from the Data and Safety Monitoring Board (DSMB) to progress to the second cohort of its EnACT study for MAT2203, an oral formulation of amphotericin B aimed at treating cryptococcal meningitis. Enrollment for the 40 patient cohort will begin soon, with the next DSMB review expected in mid-2021. MAT2203 has also been designated as a Qualified Infectious Disease Product and has Fast Track status from the FDA, enhancing its potential for addressing significant unmet medical needs.
Matinas BioPharma (MTNB) announced positive outcomes from its End of Phase 2 meeting with the FDA regarding MAT9001, an omega-3 therapy for severe hypertriglyceridemia (SHTG). The FDA agreed on the requirement for a single Phase 3 trial lasting 12 weeks, which will support a New Drug Application (NDA). Matinas aims to initiate this Phase 3 program in the first half of 2021. The alignment with FDA provides clarity for the registration pathway and the company anticipates upcoming data from its ENHANCE-IT trial against Vascepa, potentially differentiating MAT9001 and underscoring its clinical benefits.
Matinas BioPharma Holdings, Inc. (MTNB) has appointed Natasha Giordano as an independent director effective September 14, 2020. With over 25 years in healthcare leadership, her expertise will strengthen the board as the company advances its clinical development. Current board member Adam Stern will transition to a consulting role after the Annual Meeting of Stockholders on November 2, 2020, having served since the company's inception. The changes are seen as strategic moves to enhance shareholder value and support upcoming product milestones.
Matinas BioPharma Holdings (NYSE AMER: MTNB) announced that CEO Jerome D. Jabbour will join a panel at Maxim Group’s M-VEST Virtual Conference on September 17, 2020. The discussion, titled A Too Quiet Pandemic – Fungal Disease, will be moderated by analyst Jason McCarthy, Ph.D., and is set for 11:00 a.m. ET. A live audio webcast will be available on the company's website. Matinas focuses on developing therapeutics for unmet medical needs and is advancing its lead candidates, including MAT9001 and MAT2203.
Matinas BioPharma (MTNB) completed enrollment in the ENHANCE-IT Study, evaluating MAT9001 against Vascepa for reducing triglyceride levels. This head-to-head study focuses on the pharmacodynamic effects of MAT9001 and aims to establish its clinical efficacy. Topline data is expected in Q1 2021. The trial includes male and female adults with elevated triglycerides and is conducted at eight U.S. sites. The successful enrollment, achieved in under three months, is seen as a key milestone for the company, promising valuable insights into the omega-3 treatment landscape.
Matinas BioPharma Holdings (MTNB) announced that CEO Jerome D. Jabbour will present at two virtual investor conferences. The first is the LD Micro Virtual Conference on September 2, 2020, at 12:00 p.m. ET, and the second is the HC Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 12:30 p.m. ET. Both presentations will have live webcasts available on the company’s investor relations page, with replays accessible for 90 days. Matinas is focused on developing MAT9001 for cardiovascular conditions and MAT2203 for invasive fungal infections.
Matinas BioPharma Holdings (MTNB) announced positive results from the Phase 1 portion of the EnACT study for MAT2203, an oral formulation of amphotericin B for cryptococcal meningitis. Published in Antimicrobial Agents and Chemotherapy, the trial demonstrated good safety and tolerability, with reduced toxicity compared to IV amphotericin B. The ongoing Phase 2 trial aims to further evaluate MAT2203's effectiveness in treating HIV-infected patients. MAT2203 has received FDA's QIDP and orphan drug designations, signaling its potential market impact.
Matinas BioPharma Holdings (MTNB) reports second quarter financial results for 2020, continuing progress in key clinical studies while facing challenges from the COVID-19 pandemic. The ENHANCE-IT study of MAT9001 and the EnACT study of MAT2203 have resumed enrollment, with topline data from the former expected in Q1 2021. As of June 30, 2020, the company reported $68 million in cash, up from $27.8 million at the end of 2019, despite a net loss of $5.8 million. Management is optimistic about upcoming catalysts and plans to host a conference call on August 10, 2020.